Indian pharma companies are expanding in the US through acquisitions to navigate regulations, diversify portfolios, and ...

Sun Pharmaceutical Industries—controlled by Indian billionaire Dilip Shanghvi—has agreed to buy U.S.-based immunotherapy and ...

A study found Indian generics sold in the US between 2009-2018 linked to a 54% higher risk of serious side effects compared ...

India’s Contract Development and Manufacturing Organization (CDMO) market is witnessing a strong growth trajectory driven by ...

Dilip Shanghvi, chairman of India's largest drugmaker Sun Pharma, told an industry gathering last week that his company sells ...

India's Sun Pharmaceutical Industries said on Monday it will acquire Checkpoint Therapeutics, a U.S.-based immunotherapy and ...

The USFDA has established an office in India to oversee the number of Indian manufacturers qualified to supply generic ...

The Indian pharmaceutical exports ranked 11th globally in value terms in the year 2023 and accounted for 3% of the total ...

India's largest drugmaker by revenue Sun Pharmaceutical is aiming to launch its experimental anti-obesity and type 2 diabetes drug in the next four to five years, Managing Director Dilip Shanghvi said ...

Indian pharmaceutical CDMOs are anticipated to encounter minimal disruptions from the proposed US tariffs of 10-25 per cent.

Indian pharma CDMOs remain resilient, continuing to thrive due to favorable global factors. The B&K Securities report ...

The Indian Pharmaceutical Alliance (IPA) has proposed reducing the import duty on pharma products from the US to zero.